Cargando…
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases
Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile compared with vitamin K antagonists. However, the lack of specific reversal agents has made the management of some patients receiving long-term treatment with NOACs problematic in emergency situations such as...
Autores principales: | Vosko, Milan R., Bocksrucker, Christof, Drwiła, Rafał, Dulíček, Petr, Hauer, Tomas, Mutzenbach, Johannes, Schlimp, Christoph J., Špinler, David, Wolf, Thomas, Zugwitz, Daša |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337234/ https://www.ncbi.nlm.nih.gov/pubmed/28210988 http://dx.doi.org/10.1007/s11239-017-1476-2 |
Ejemplares similares
-
Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
por: Mutzenbach, Johannes Sebastian, et al.
Publicado: (2016) -
Idarucizumab: A novel antidote for reversal of dabigatran
por: Rehman, Abdul, et al.
Publicado: (2016) -
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage
por: Balakumar, Jonathan, et al.
Publicado: (2017) -
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018) -
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
por: Sié, Pierre
Publicado: (2016)